Demyelination as a complication of new immunomodulatory treatments

Current Opinion in Neurology

Volumn 23, Issue 3, 2010, Pages 226-233

  Lysandropoulos, Andreas P ^a   Du Pasquier, Renaud A ^b  

^a Department of Clinical Neurosciences ^*  (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antitumor necrosis factor alpha agents; Demyelination; Efalizumab; MAbs; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy; Rituximab

Indexed keywords

ADALIMUMAB; ALPHA4 INTEGRIN; ANTIRETROVIRUS AGENT; BETA1A INTERFERON; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; EFALIZUMAB; ETANERCEPT; ETOPOSIDE; INFLIXIMAB; LENERCEPT; MEFLOQUINE; MONOCLONAL ANTIBODY; NATALIZUMAB; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLERGIC ENCEPHALOMYELITIS; ANKYLOSING SPONDYLITIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CEREBROSPINAL FLUID ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CROHN DISEASE; CYTOMEGALOVIRUS RETINITIS; DEMYELINATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME RECONSTITUTION; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOMODULATION; IMMUNOSURVEILLANCE; JC VIRUS; LEWIS SUMMER SYNDROME; LYMPHOMA; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; OPTIC NEURITIS; PLASMAPHERESIS; PNEUMONIA; POLYMERASE CHAIN REACTION; POLYNEUROPATHY; POLYRADICULONEUROPATHY; POSTMARKETING SURVEILLANCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SEROPREVALENCE; SURVIVAL RATE; VIRION;

ANIMALS; ANTIBODIES, MONOCLONAL; DEMYELINATING DISEASES; HUMANS; IATROGENIC DISEASE; IMMUNOLOGIC FACTORS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; NERVOUS SYSTEM; RISK ASSESSMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951968828     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283398c96     Document Type: Review

References (96)

1. Kö hler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature;1975;256:495-497.
2. Rose JW, Foley JF, Carlson NG. Monoclonal antibody treatments for multiple sclerosis. Curr Treat Options Neurol 2009; 11:211-220.
3. Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958; 81:93-111.
4. Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 2006; 60:162-173.
5. Ammassari A, Cingolani A, Pezzotti P, et al. AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology 2000; 55:1194-1200.
6. Gheuens S, Pierone G, Peeters P, Koralnik IJ. Progressive multifocal leu-koencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry 2010; 81:247-254.
7. Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009; 199:837-846.
8. Major EO, Amemiya K, Tornatore CS, et al. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 1992; 5:49-73.
9. Tan CS, Dezube BJ, Bhargava P, et al. Detection of JC virus DNAand proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 2009; 199:881-888.
10. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoence-phalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834-4840.
11. Du Pasquier RA, Schmitz JE, Jean-Jacques J, et al. Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. J Virol 2004; 78:10206-10210.
12. Perez-Liz G, Del Valle L, Gentilella A, et al. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol 2008; 64:379-387.
13. Du Pasquier RA, Corey S, Margolin DH, et al. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology 2003; 61:775-782.
14. Koralnik IJ, Wuthrich C, Dang X, et al. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 2005; 57:576-580.
15. Wuthrich C, Cheng YM, Joseph JT, et al. Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 2009; 68:15-25.
16. Granot R, Lawrence R, Barnett M, et al. What lies beneath the tent? JC-virus cerebellar granule cell neuronopathy complicating sarcoidosis. J Clin Neu-rosci 2009; 16:1091-1092.
17. Tan IL, BrewBJ. Possible JCV granular cell neuronopathy in a patient with HIV infection. Neurology 2009; 73:1598-1599.
18. Wenning W, Haghikia A, Laubenberger J, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009; 361:1075-1080.
19. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354:924-933.
20. Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009; 361:1081-1087.
21. Ryschkewitsch C, Jensen P, Hou J, et al. Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods 2004; 121:217-221.
22. IacobaeusE, Ryschkewitsch C, Gravell M, et al. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. Mult Scler 2009; 15:28-35.
23. Major EO. Progressive multifocal leukoencephalopathy in patients on immu-nomodulatory therapies. Annu Rev Med 2010; 61:35-47.
24. Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active anti-retroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003; 9 (Suppl 1):47-53.
25. ElphickGF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004; 306:1380-1383.
26. Vulliemoz S, Lurati-Ruiz F, Borruat FX, et al. Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. J Neurol Neurosurg Psychiatry 2006; 77:1079-1082.
27. Lanzafame M, Ferrari S, Lattuada E, et al. Mirtazapine in an HIV-1 infected patient with progressive multifocal leukoencephalopathy. Infez Med 2009; 17:35-37.
28. Verma S, Cikurel K, Koralnik IJ, et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis 2007; 196:709-711.
29. Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 2009; 53:1840-1849.
30. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005; 4:510-518.
31. Coisne C, Mao W, Engelhardt B. Cutting edge: natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J Immunol 2009; 182:5909-5913.
32. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899-910.
33. RudickRA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354:911-923.
34. Edula RG, Picco MF. An evidence-based review of natalizumab therapy in the management of Crohn's disease. Ther Clin Risk Manag 2009; 5:935-942.
35. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencepha-lopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353:369-374.
36. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoen-cephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353:375-381.
37. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoen-cephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353:362-368.
38. Wiendl H, Toyka KV, Rieckmann P, et al. Basic and escalating immunomo-dulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008; 255:1449-1463.
39. Major EO. Reemergence of PML in natalizumab-treated patients: new cases, same concerns. N Engl J Med 2009; 361:1041-1043.
40. Bonig H, Wundes A, Chang KH, et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008; 111:3439-3441.
41. + hematopoietic progenitor cells in humans. Blood 2008; 111:3893-3895.
42. Ransohoff RM. Natalizumab and PML. Nat Neurosci 2005; 8:1275.
43. Varnier O, McDermott J, Giacomazzi C. Non invasive surveillance of JCV reactivation in blood and urine from natalizumab treated MS patients, blood donors and immunocompromised patients identifies two PML cases in HIV and congenital immunodeficiency patients. Mult Scler 2009; 15:S276-S277.
44. Warnke C, Adams O, Kieseier BC. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361:2489; author reply 2489-2490.
45. JilekS, Jaquiery E, Hirsch HH, et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and long itudinal study. Lancet Neurol 2010; 9:264-272.
46. Rudick R, Polman C, O'Connor P. Evaluation of natalizumab treatment on the presence of JC virus in blood or urine from multiple sclerosis patients. Mult Scler 2009; 15:S274-S275.
47. Gorelik L, Goelz S, Sandrock AW. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361:2487-2488; author reply 2489-2490.
48. Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361:1067-1074.
49. Du Pasquier RA, Kuroda MJ, Zheng Y, et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004; 127:1970-1978.
50. Berger J, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab: unforeseen consequences. N Engl J Med 2005; 353:414-416.
51. Becher B. Central nervous system immune surveillance: on natalizumab, dendritic cells, and dangerous immune privilege. Arch Neurol 2008; 65: 1566-1567.
52. + T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008; 65:1596-1603.
53. Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006; 59:743-747.
54. Du Pasquier RA, AutissierP, Zheng Y, et al. Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. AIDS 2005; 19:2069-2076.
55. Hartung HP. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 2009; 8:28-31.
56. Berger JR, Houff S. Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann Neurol 2009; 65:367-377.
57. Zecca C, Nessi F, Bernasconi E, Gobbi C. Ocular toxoplasmosis during natalizumab treatment. Neurology 2009; 73:1418-1419.
58. Schweikert A, Kremer M, Ringel F, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2009; 66:403-406.
59. DeAngelis LM. Natalizumab: a double-edged sword? Ann Neurol 2009; 66:262-263.
60. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009; 72:402-409.
61. Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009; 72:1458-1464.
62. Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003; 9 (Suppl 1):25-31.
63. Wuthrich C, Kesari S, Kim WK, et al. Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: co-localization of CD8(+) T cells with JCV-infected glial cells. J Neurovirol 2006; 12:116-128.
64. Tubridy N, Behan PO, Capildeo R, et al. The effect of antialpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999; 53:466-472.
65. Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008; 70:1150-1151.
66. Stuve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 2009; 72:396-401.
67. Schiess N, Calabresi PA. Natalizumab: bound to rebound? Neurology 2009; 72:392-393.
68. Molloy ES, Calabrese LH. Therapy: Targeted but not trouble-free: efalizumab and PML. Nat Rev Rheumatol 2009; 5:418-419.
69. Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 2009; 145:937-942.
70. Martin Mdel P, Cravens PD, Winger R, et al. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol 2009; 66:1016-1020.
71. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10:816-824.
72. Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180:63-70.
73. Stuve O, LeussinkVI, Frohlich R, et al. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol 2009; 66:259-261.
74. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676-688. (Pubitemid 351240747)
75. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008; 63:395-400. (Pubitemid 351499869)
76. WingerchukDM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol 2008; 10:55-66.
77. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64:1270-1272.
78. Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 2008; 67 (Suppl 3):iii64-iii65.
79. Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritrans-plantation rituximab. Blood 2002; 99:1486-1488.
80. Kamar N, Mengelle C, Rostaing L. Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients. Am J Transplant 2009; 9:244-245.
81. Andreakos E. Targeting cytokines in autoimmunity: new approaches, new promise. Expert Opin Biol Ther 2003; 3:435-447.
82. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991; 87:949-954.
83. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325:467-472.
84. Selmaj KW, Raine CS. Experimental autoimmune encephalomyelitis: immu-notherapy with antitumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 1995; 45:S44-S49.
85. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal antitumor necrosis factor antibody cA2. Neurology 1996; 47:1531-1534.
86. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457-465.
87. Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 2008; 87:345-364.
88. Ramos-Casals M, Roberto Perez A, Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010; 9:188-193.
89. Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005; 128:376-392.
90. Zheng L, Fisher G, Miller RE, et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995; 377:348-351.
91. Cope A, Ettinger R, McDevitt H.The role of TNF alpha and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol 1997; 148:307-312.
92. Roos JC, Ostor AJ. Neurological complications of infliximab. J Rheumatol 2007; 34:236-237; author reply 237-238.
93. Rau R, Sander O, van Riel P, et al. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis. J Rheumatol 2003; 30:680-690.
94. Toussirot E, Wendling D.The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother 2004; 5:581-594.
95. Winkelmann A, Patejdl R, Wagner S, et al. Cerebral MRI lesions and antitumor necrosis factor-alpha therapy. J Neurol 2008; 255 (Suppl 6):109-114.
96. Braun J, Sieper J. Biological therapies in the spondyloarthritides: the current state. Rheumatology (Oxford) 2004; 43:1072-1084.